Astellas Pharma (OTCMKTS:ALPMY) Shares Pass Above 50-Day Moving Average – Time to Sell?

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $13.54 and traded as high as $14.8610. Astellas Pharma shares last traded at $14.79, with a volume of 105,914 shares.

Analysts Set New Price Targets

Separately, Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Astellas Pharma presently has an average rating of “Hold”.

Astellas Pharma Stock Performance

The stock has a 50-day moving average price of $13.58 and a 200 day moving average price of $14.65. The company has a quick ratio of 0.90, a current ratio of 1.17 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $26.64 billion, a price-to-earnings ratio of 11.20 and a beta of 0.08.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).